期刊文献+

丙戊酸抗乳腺癌作用研究进展 被引量:1

Research progress of valproic acid on breast cancer
下载PDF
导出
摘要 目的对近年来关于丙戊酸抗乳腺癌方面的相关研究做一综述,为进一步研究丙戊酸抗乳腺癌的作用机制,以及丙戊酸在治疗乳腺癌方面的临床应用提供参考。方法通过在中国知网、Pubmed、GeenMedical等数据库检索国内外关于丙戊酸抗乳腺癌的相关文献并对文献内容进行归纳总结。结果分析多篇文献可以发现,丙戊酸可以分别通过不同机制对乳腺癌产生抑制作用,具体机制包括诱导细胞周期停滞和凋亡,抑制细胞迁移,以及影响乳腺癌干细胞等。此外丙戊酸还可以通过干扰DNA修复途径作为乳腺癌治疗的放射增敏剂,并且可作为乳腺癌化疗的协同药物。结论丙戊酸可以从多方面抑制乳腺癌,这为乳腺癌靶向治疗提供了新的研究方向。 Objective To review the relevant research of valproic acid on the anti-breast cancer in recent years,so as to provide reference for further research on the mechanism of valproic acid against breast cancer and the clinical application of valproic acid in the treatment of breast cancer.Methods It was finished by searching domestic and foreign related literatures on valproic acid against breast cancer in databases such as CNKI,Pubmed,GeenMedical,and summarizing the content of the literature.Results It was found that valproic acid can inhibit breast cancer through different mechanisms by analyzing of numerous literatures,inducing cell cycle arrest and apoptosis,inhibiting cell migration,and affecting breast cancer stem cells.In addition,valproic acid was also used as a radiosensitizer for breast cancer treatment by interfering with DNA repair pathways,and was used as a synergistic drug for breast cancer chemotherapy.Conclusion Valproic acid can inhibit breast cancer in many ways,which provides a new research direction for breast cancer targeted therapy.
作者 籍云霞 张庆镐 刘双萍 JI Yunxia;ZHANG Qinggao;LIU Shuangping(School of Medicine,Dalian University,Dalian 116622,China)
机构地区 大连大学医学院
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2022年第4期482-488,512,共8页 Journal of Shenyang Pharmaceutical University
基金 国家自然科学基金资助项目(NSFC:61671098,31560312)。
关键词 丙戊酸 乳腺癌 组蛋白去乙酰化酶抑制剂 放射增敏 联合用药 valproic acid breast cancer histone deacetylase inhibitor radiosensitization combination medication
  • 相关文献

参考文献4

二级参考文献13

  • 1熊芳,肖大光,曾朝阳,熊炜,阳菊华.利用基因表达系列分析数据库进行数字化基因差异显示筛选胃癌相关基因[J].中国医师杂志,2006,8(3):302-305. 被引量:2
  • 2Yu-Ping Xiao,Dong-Ying Wu,Lei Xu,Yan Xin.Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma[J].World Journal of Gastroenterology,2006,12(23):3766-3769. 被引量:6
  • 3Ishihama K, Yamakawa M, Semba S, Takeda H, et al. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol, 2007,60( 11 ) : 1205-1210.
  • 4Turner BM. Cellular memory and the histone code. Cell, 2002, 111 (3) : 285 -291.
  • 5Dokmanovic M;Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem ,2005,96 (2) : 293 -304.
  • 6Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nature ,2001,1 ( 3 ) : 194-202.
  • 7Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res, 2005, 29(7) :739-748.
  • 8Tabe Y, Konopleva M, Contractor R, et al. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood, 2006,107(4) :1546-1554.
  • 9Liu T, Tee AE, Porto A, et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Natl Acad Sci U S A,2007,104(47) :18682-18687.
  • 10Taunton J, Hassig C A, Schreiber S L. A mammalian histone deacetylase related tothe yeast transc fiptional regulator Rpd3p. Science, 1996,272 (5260): 408-411.

共引文献18

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部